DP
UNCY icon

Diadema Partners’s Unicycive Therapeutics UNCY Stock Holding History

Diadema Partners’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
303,676
+197,593
+186% +$1.46M 0.18% 94
2026
Q1 		$698K Buy
+106,083
New +$695K 0.12% 99

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Diadema Partners's UNCY Position: Q2 2026 in Review

Diadema Partners increased its Unicycive Therapeutics (UNCY) stake by 186% in Q2 2026, buying an estimated $1.46M and bringing the position to 303,676 shares worth $1.42M. The position accounts for 0.18% of the portfolio, ranked #94.

Diadema Partners first reported a position in UNCY in Q1 2026 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Diadema Partners held 303,676 shares of Unicycive Therapeutics worth $1.42M as of Q2 2026.
  • Diadema Partners bought 197,593 Unicycive Therapeutics shares in Q2 2026, an estimated $1.46M.
  • Unicycive Therapeutics made up 0.18% of Diadema Partners's portfolio in Q2 2026, its #94 holding.
  • Diadema Partners first reported a position in Unicycive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.